IL-17A inhibition improves skin lesions and early atherosclerosis markers in psoriasis vulgaris patients
Psoriasis Is Linked to Heart Disease — and One Drug May Help Both
This retrospective cohort and prospective intervention study evaluated IL-17A inhibitors for psoriasis vulgaris and associated cardiovascula…
Psoriasis and heart disease share deep biological roots, and a specific drug may improve both conditions at once.
Higher composite dietary antioxidant index associated with lower all-cause mortality in psoriasis patients
Higher dietary antioxidants linked to lower death risk in psoriasis patients
This prospective cohort study evaluated 500 individuals with psoriasis from the NHANES database.
Psoriasis patients who eat more antioxidants face a lower risk of death, according to a study tracking 500 people over more than a decade.
CXCL13 quantification in PBMCs and plasma distinguishes Sézary syndrome from other cutaneous T-cell lymphomas and dermatoses
A simple blood test could spot a rare skin cancer faster
This cohort study analyzed CXCL13 expression in peripheral blood mononuclear cells (PBMCs) and plasma concentrations in patients with suspec…
A simple blood test for a protein called CXCL13 may help doctors catch a rare, aggressive skin cancer that often looks like eczema for years…
Secukinumab improves cutaneous adipose tissue inflammatory signatures in psoriasis patients
Fat Under Your Skin Fuels Psoriasis Inflammation
This randomized placebo-controlled trial evaluated secukinumab in 82 patients with psoriasis.
Your body fat is not just storing energy; it is actively making your psoriasis worse, and new treatments are finally targeting this hidden f…
Network meta-analysis finds biologics superior to placebo for pediatric plaque psoriasis
Biologic treatments help children with moderate to severe psoriasis, analysis finds
A network meta-analysis of randomized controlled trials including 1,016 pediatric psoriasis patients found all biologic therapies significan…
Biologic medicines help children with moderate to severe psoriasis achieve clear skin and better quality of life, analysis finds.
Bimekizumab maintains complete skin clearance in 73% of psoriasis patients at 4 years
Can psoriasis treatment keep skin clear for years? New data suggests it might
A pooled analysis of phase 3 trials and open-label extension in 503 psoriasis patients found 73.0% of those achieving complete clearance at …
After four years on bimekizumab, about 73% of patients with psoriasis kept their skin completely clear, suggesting the treatment may help re…
Oral ME3183 shows higher PASI-75 response rates than placebo in moderate to severe plaque psoriasis trial
Could a new pill help clear stubborn psoriasis skin plaques?
A 16-week randomized controlled trial in 132 patients with moderate to severe plaque psoriasis found higher proportions achieving ≥75% PASI …
A new oral pill helped over 60% of patients with moderate to severe psoriasis clear skin plaques significantly better than a placebo in a re…
Guselkumab Shows Improvement in Inverse Psoriasis in Single Case Report
Can a psoriasis drug help with a rare, hard-to-treat skin condition?
A case report and literature review describes a 48-year-old male with inverse psoriasis who showed marked improvement in cutaneous lesions a…
A single patient with hard-to-treat inverse psoriasis found marked relief in itching and skin lesions after just three injections of a newer…
Phase 2a study of bimekizumab in chronic plaque psoriasis reports pharmacokinetics and PASI change at Week 28
Could a new psoriasis treatment work better by targeting two inflammation sources at once?
A Phase 2a, multicenter, randomized, subject- and investigator-blind study investigated the pharmacokinetics, pharmacodynamics, and safety o…
A new psoriasis drug targets two inflammation sources to see if it works better for thick, scaly skin patches in adults.
Phase 3 trial compares bimekizumab to placebo and ustekinumab for moderate to severe plaque psoriasis
Can a new psoriasis drug outperform an established treatment?
A phase 3 randomized controlled trial enrolled 567 adults with moderate to severe chronic plaque psoriasis to compare bimekizumab against pl…
A new psoriasis drug called bimekizumab is being tested against existing treatments in a major trial involving 567 adults to see if it helps…
Phase 3 trial of bimekizumab versus placebo in 435 adults with moderate to severe plaque psoriasis
Can a new drug help people with moderate to severe plaque psoriasis?
A phase 3 randomized controlled trial evaluated bimekizumab versus placebo in 435 adults with moderate to severe chronic plaque psoriasis.
A new drug tested in a large study aims to help clear skin for people with moderate to severe plaque psoriasis.
Sliding Cupping Therapy Matches NBUVB in Psoriasis Severity Reduction at 8 Weeks
Could Sliding Cupping Therapy Be a Game-Changer for Psoriasis Patients?
In a RCT with 60 psoriasis patients, sliding cupping showed similar efficacy to NBUVB in reducing PASI scores by 62.4% vs. 66.9% (P=.526).
Sliding cupping therapy improved psoriasis symptoms just as well as standard light treatment, offering a viable alternative for patients see…
Questions about Psoriasis
Are there regional differences in health issues for people with psoriasis?
Yes, regional differences exist in psoriasis-related health issues, including comorbidities, treatment patterns, and healthcare access, as shown by studies from North America, Europe, Asia, and Africa.
Full answer →Is secukinumab effective for Chinese patients with psoriatic arthritis?
Yes, secukinumab is effective for Chinese patients with psoriatic arthritis, with real-world data and cost-effectiveness analyses supporting its use.
Full answer →